NKTR NKTR

$57.06 ▼ -3.91% ($-2.32)

Open $59.77

Prev Close $59.38

Day Range $57.04 – $60.98

📋 Company Profile

Employees	63
Listed	1994-05-03
Shares Out.	34,142,994
Website	nektar.com ↗
Revenue	$10.1M
Gross Profit	$10.1M
Net Income	-$40.6M
Free Cash Flow	-$234.0M
Total Assets	$1.10B
Total Liabilities	$192.0M
Equity	$903.1M

About NKTR

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

NKTR is a publicly traded company under the ticker symbol NKTR. Quotes and metrics shown here are sourced from public market data and refreshed regularly.